NCT06325683: An ongoing trial by National Cancer Institute (NCI)
This trial is ongoing. It must report results 3 years from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06325683 |
|---|---|
| Title | Randomized Phase II Trial of Anti-Lag-3 and Anti-PD-1 Blockade vs. SOC in Patients With Recurrent Glioblastoma |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 8, 2024 |
| Completion date | July 15, 2028 |
| Required reporting date | July 15, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | June 15, 2026 |
| Days late | None |